A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)

Merck Sharp & Dohme LLC37 enrolled

Overview

The purpose of this study is to learn about the safety of enlicitide chloride and how well people tolerate it. Researchers also want to learn what happens to different amounts of enlicitide chloride in a healthy person's body over time.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

Enlicitide ChlorideDRUG

Oral Capsule

PlaceboDRUG

Placebo oral capsule matching enlicitide chloride

Eligibility

Sex: MALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Inclusion criteria include, but are not limited to: * Is in good health * Has a body mass index ≥19.0 and ≤26.0 kg/m\^2, inclusive Exclusion Criteria: Exclusion criteria include, but are not limited to: * Has a history of gastrointestinal disease * Has a history of cancer (malignancy)

Locations (1)

Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 0001)

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Number of Participants Who Experience an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

Time frame: Up to approximately 2 months

Number of Participants Who Discontinue the Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

Time frame: Up to approximately 2 months

Secondary Outcomes

Panels A and B: Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) of Enlicitide Chloride

Blood samples will be collected to determine the AUC0-inf of enlicitide chloride